Enzmann Gaby U, Benton Richard L, Talbott Jason F, Cao Qilin, Whittemore Scott R
Kentucky Spinal Cord Injury Research Center, Louisville, Kentucky 40202, USA.
J Neurotrauma. 2006 Mar-Apr;23(3-4):479-95. doi: 10.1089/neu.2006.23.479.
Stem cells hold great promise for therapeutic repair after spinal cord injury (SCI). This review compares the current experimental approaches taken towards a stem cell-based therapy for SCI. It critically evaluates stem cell sources, injury paradigms, and functional measurements applied to detect behavioral changes after transplantation into the spinal cord. Many of the documented improvements do not exclusively depend on lineage-specific cellular differentiation. In most of the studies, the functional tests used cannot unequivocally demonstrate how differentiation of the transplanted cells contributes to the observed effects. Standardized cell isolation and transplantation protocols could facilitate the assessment of the true contribution of various experimental parameters on recovery. We conclude that at present embryonic stem (ES)-derived cells hold the most promise for therapeutic utility, but that non-neural cells may ultimately be optimal if the mechanism of possible transdifferentiation can be elucidated.
干细胞在脊髓损伤（SCI）后的治疗修复方面具有巨大潜力。本综述比较了目前针对基于干细胞的SCI治疗所采用的实验方法。它批判性地评估了干细胞来源、损伤模型以及用于检测移植到脊髓后行为变化的功能测量方法。许多已记录的改善并非完全依赖于谱系特异性细胞分化。在大多数研究中，所使用的功能测试无法明确证明移植细胞的分化如何导致观察到的效果。标准化的细胞分离和移植方案有助于评估各种实验参数对恢复的真正贡献。我们得出结论，目前胚胎干细胞（ES）衍生的细胞在治疗应用方面最具潜力，但如果能够阐明可能的转分化机制，非神经细胞最终可能是最佳选择。
